A detailed history of High Tower Advisors, LLC transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 50,692 shares of INKT stock, worth $37,005. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,692
Previous 50,880 0.37%
Holding current value
$37,005
Previous $46,000 4.35%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.87 - $1.56 $163 - $293
-188 Reduced 0.37%
50,692 $48,000
Q1 2024

May 06, 2024

SELL
$0.84 - $1.12 $51 - $68
-61 Reduced 0.12%
50,880 $46,000
Q4 2023

Feb 12, 2024

BUY
$0.88 - $1.21 $30,384 - $41,778
34,528 Added 210.37%
50,941 $54,000
Q3 2023

Nov 08, 2023

SELL
$1.1 - $2.09 $618 - $1,174
-562 Reduced 3.31%
16,413 $18,000
Q2 2023

Aug 14, 2023

BUY
$0.89 - $3.33 $5,851 - $21,894
6,575 Added 63.22%
16,975 $35,000
Q3 2022

Nov 09, 2022

BUY
$1.19 - $3.4 $12,376 - $35,360
10,400 New
10,400 $22,000

Others Institutions Holding INKT

About MiNK Therapeutics, Inc.


  • Ticker INKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,775,100
  • Market Cap $24.7M
  • Description
  • MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...
More about INKT
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.